导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.51% | 3947/4773 |
| 近一周 | -2.71% | 4185/5465 |
| 近一月 | -3.33% | 2389/5421 |
| 近一季 | -1.39% | 1203/5231 |
| 近半年 | -12.97% | 3850/4920 |
| 近一年 | -15.44% | 3746/4394 |
| 近两年 | 29.04% | 2324/2954 |
| 近三年 | 13.02% | 1679/2253 |
| 成立以来 | 58.77% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.41% 4130/4961 |
-10.11% 4048/5312 |
- - |
- - |
| 2025 | 18.17% 2338/4813 |
6.67% 599/3635 |
-0.74% 3015/4076 |
17.96% 2382/4524 |
-5.40% 3553/4813 |
| 2024 | 17.94% 635/3463 |
1.68% 863/2808 |
1.22% 488/3014 |
15.06% 1829/3129 |
-0.40% 1408/3463 |
| 2023 | -7.41% 919/2656 |
6.75% 651/2280 |
-4.26% 1111/2385 |
-4.18% 1080/2515 |
-5.44% 1358/2655 |
| 2022 | -10.01% 193/2207 |
-8.03% 267/1919 |
2.65% 1275/2016 |
-11.21% 508/2113 |
7.35% 317/2208 |
| 2021 | 6.29% 519/1822 |
4.53% 147/1255 |
3.27% 977/1330 |
-0.41% 495/1466 |
-1.12% 1313/1822 |
| 2020 | 21.70% 688/1250 |
-8.48% 613/1028 |
15.51% 492/1067 |
6.56% 829/1164 |
8.04% 689/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华夏AH经济蓝筹股票C VS. 长安沪深300非周期A(740101) |